高LDL和低HDL都是发生心脏疾病的严重危险因素; 他汀类药物仍是降低LDL的一线治疗药物 但若仅仅是降低LDL则没有益处; 他汀类药物与氯贝丁酯类药物联合就可以既降低LDL又可以提高HDL的水平; 他汀类药物几乎彻底占据了高胆固醇和高脂血症的治疗 市场,但是卫生保健系统的人员需要意识到,仍有其他一些 药物也有其一定的地位。患者如果不能通过改善生活方式来 调节血脂,或他汀类药物对其不是十分有效时,就可选择如 氯贝丁酯类和烟酸类的药物,或进行联合治疗。 Both high and low HDLs are serious risk factors for developing heart disease; statins are still first-line therapies that lower LDL but do not help if LDL alone; statins and clofibrate both combine Lowering LDL also increases HDL levels; statins almost completely occupy the market for the treatment of hypercholesterolemia and hyperlipidemia, but people in the health care system need to be aware that there are still other drugs that have their place. Patients can choose drugs such as clofibrate and nicotinic acid, or they can be given a combination therapy if they can not adjust their blood lipids by improving their lifestyle, or when they are not very effective with statins.